SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Nektar Therapeutics (NKTR) News

Follow Nektar Therapeutics (NKTR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 25 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol NKTR Asset equity Sector Markets 90 days 19 Last 30.26 Updated Oct 27, 2026, 10:01 PM UTC Open live news feed Open NKTR chart & news
M Nektar Therapeutics to Report Q3 2026 Results Nov. 12 After Close Nektar Therapeutics will release its Q3 2026 financial results on Nov. 12 after the U.S. market close, followed by a conference call at 5:00 p.m. ET. EQUITY | Oct 27, 2026, 10:01 PM UTC M NKTR Stock Plunges on Rezpegaldesleukin Data; William Blair Maintains Durability View Nektar Therapeutics (NKTR) shares dropped 21% on Thursday after the company presented new response rate data for its experimental skin drug, rezpegaldesleukin. While the drug reportedly maintained efficacy after treatmen EQUITY | Oct 01, 2026, 07:42 PM UTC L Weekly Recap: Phase 3 ZENITH AD trials and $90M jury award Nektar Therapeutics (NASDAQ:NKTR) is advancing rezpegaldesleukin with two global Phase 3 ZENITH AD trials (a third planned) even as Wedbush flags safety/efficacy concerns and a $50 target, the company won a $90M jury awa NEWS | Sep 28, 2026, 11:04 AM UTC L Nektar Therapeutics Price Target Maintained With a $178.00/Share by BTIG Ratings actions from Benzinga NEWS | Sep 28, 2026, 10:11 AM UTC L BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00.The price target implies an upside of 212.0% from the Sep 25 close of $57.06.Key takeaways from the analyst noteStrong Clinic EQUITY | Sep 28, 2026, 10:01 AM UTC L Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Sept. 25, 2026 // -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on September 18, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock op EQUITY | Sep 25, 2026, 08:15 PM UTC H Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says By Blake BrittainA federal jury in California has determined that Eli Lilly NYSE:LLY must pay Nektar Therapeutics NASDAQ:NKTR $90 million for breaking an agreement related to an autoimmune drug candidate that the compani NEWS | Sep 25, 2026, 03:14 PM UTC L Nektar Therapeutics Price Target Maintained With a $178.00/Share by BTIG Ratings actions from Benzinga NEWS | Sep 25, 2026, 02:42 PM UTC L BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00.The price target implies an upside of 199.8% from the Sep 24 close of $59.38.Key takeaways from the analyst noteStrong Safety EQUITY | Sep 25, 2026, 02:32 PM UTC L Nektar Gets $90 Million Jury Award in Breach Suit Against Eli Lilly — Update By Colin KellaherNektar Therapeutics said it has won a $90 million verdict in its lawsuit against Eli Lilly related to the development of its proposed autoimmune drug rezpegaldesleukin, or rezpeg.Nektar on Friday said a REGULATION | Sep 25, 2026, 01:37 PM UTC L Nektar Gets $90 Million Jury Award in Breach Suit Vs Eli Lilly By Colin KellaherNektar Therapeutics said it has won a $90 million verdict in its lawsuit against Eli Lilly related to the development of its proposed autoimmune drug Rezpegaldesleukin, or rezpeg.Nektar said a California REGULATION | Sep 25, 2026, 12:09 PM UTC L Nektar Therapeutics awarded $90M jury verdict against Eli Lilly over rezpegaldesleukin dispute Nektar Therapeutics won a $90 million jury verdict finding Eli Lilly breached the implied covenant under their rezpegaldesleukin license agreement.Key Highlights:Original SEC Filing: NEKTAR THERAPEUTICS [ NKTR ] - 8-K - REGULATION | Sep 25, 2026, 11:04 AM UTC L Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant Of Good Faith In License Agreement Eli Lilly and Company NYSE:LLY NEWS | Sep 25, 2026, 11:03 AM UTC L Nektar Therapeutics Is Maintained at Neutral by Wedbush Ratings actions from Benzinga NEWS | Sep 23, 2026, 12:29 PM UTC L Wedbush maintains Neutral rating on Nektar Therapeutics, $50 price target Wedbush maintained their Neutral rating on Nektar Therapeutics's stock with a price target of $50.00.The price target implies a downside of 18.0% from the Sep 22 close of $60.97.Key takeaways from the analyst noteConcern EQUITY | Sep 23, 2026, 12:19 PM UTC L Nektar Therapeutics price target maintained at $178 by BTIG BTIG maintained a $178.00/share price target for Nektar Therapeutics. EQUITY | Sep 09, 2026, 10:29 AM UTC L Nektar enters quiet period ahead of REZOLVE-AA follow-up data Nektar said its quiet period began Sept. 8, 2026, ahead of 24-week off-treatment follow-up data from the Phase 2b REZOLVE-AA study of rezpegaldesleukin. REGULATION | Sep 08, 2026, 08:13 PM UTC L Nektar Therapeutics reports inducement grants under Nasdaq Rule 5635(c)(4) Nektar Therapeutics (NKTR) reports inducement grants under Nasdaq listing rule 5635(c)(4). EQUITY | Aug 28, 2026, 08:18 PM UTC L Nektar (NKTR) publishes positive Phase 2b REZOLVE-AD 16-week results in The Lancet Nektar announces publication in The Lancet of positive Phase 2b REZOLVE-AD 16-week induction results for rezpegaldesleukin in moderate-to-severe atopic dermatitis. EQUITY | Aug 25, 2026, 12:30 PM UTC L JPMorgan initiates NKTR at Neutral with $65 price target JPMorgan initiates coverage of NKTR with a Neutral rating and a $65.00 price target. EQUITY | Aug 21, 2026, 11:58 AM UTC L Nektar Therapeutics reports Second Quarter 2026 financial results Nektar Therapeutics (NKTR) announces its Second Quarter 2026 financial results, but the feed provides no further figures or guidance details. EARNINGS | Aug 13, 2026, 08:15 PM UTC L NKTR NKTR - Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets NKTR NKTR - Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets EARNINGS | Jul 28, 2026, 10:00 PM UTC L NKTR Maintain Buy and $151 PT after Ph3 Initiation in Ad Marks Key Milestone for Rezpeg @ Citi NKTR Maintain Buy and $151 PT after Ph3 Initiation in Ad Marks Key Milestone for Rezpeg @ Citi EQUITY | Jul 22, 2026, 01:08 PM UTC L NKTR Initiated Buy W/$153.00 PT at Canaccord NKTR Initiated Buy W/$153.00 PT at Canaccord EQUITY | Jul 22, 2026, 12:02 PM UTC L NKTR Nektar Therapeutics announces start of phase 3 zenith Ad program evaluating novel regulatory T-cell biologic rezpegaldesleukin in moder NKTR Nektar Therapeutics announces start of phase 3 zenith Ad program evaluating novel regulatory T-cell biologic rezpegaldesleukin in moderate-to-severe atopic dermatitis Nektar Therapeutics - initial phase 3 topline da EQUITY | Jul 21, 2026, 11:04 AM UTC